8-K: IMUNON Faces Nasdaq Delisting Threat Over Bid Price and Equity Deficiencies

IMUNON, Inc. has received a delisting determination from Nasdaq due to its failure to meet the minimum bid price and stockholders' equity requirements, though the company intends to appeal the decision.

Summary

• IMUNON, Inc. received a delisting determination letter from Nasdaq on May 28, 2025.
• The delisting is primarily due to the company's failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
• Additionally, the company failed to meet the minimum stockholders' equity requirement of $5,000,000 for continued listing on The Nasdaq Capital Market, as per Nasdaq Listing Rule 5550(b)(1) and 5505(b).
• IMUNON is not eligible for a 180-calendar day extension for the bid price deficiency because it did not meet the minimum stockholders' equity initial listing requirements.
• Trading of IMUNON's common stock is scheduled to be suspended at the opening of business on June 6, 2025, and subsequently delisted from Nasdaq, unless the company requests a hearing by June 4, 2025.
• The company intends to request a hearing before a Nasdaq Hearing Panel to appeal the determination, expecting this request to stay the suspension and delisting pending the hearing process.
• IMUNON plans to present a compliance plan to the Panel, which may include a reverse stock split, subject to Board and stockholder approval.

Sentiment

Score: 2

Explanation: The document conveys a highly negative sentiment due to the imminent delisting from Nasdaq, driven by failures to meet critical listing requirements. While the company plans to appeal, the outcome is uncertain, and delisting poses significant risks to liquidity, stock price, and future capital raising ability.

Positives

• The company intends to appeal the delisting determination, which is expected to stay the suspension of trading and delisting pending the hearing process.
• The company plans to provide a strategy to regain compliance, including the potential implementation of a reverse stock split.

Negatives

• IMUNON, Inc. received a delisting determination letter from Nasdaq.
• The company failed to meet the Nasdaq minimum bid price requirement of $1.00 per share.
• The company failed to meet the Nasdaq minimum stockholders' equity requirement of $5,000,000.
• The company is not eligible for an extension to regain compliance with the minimum bid price requirement due to its failure to meet the stockholders' equity requirement.
• Trading of the common stock is scheduled for suspension on June 6, 2025, if an appeal is not filed by June 4, 2025.

Risks

• There is no assurance that the company will be able to regain compliance with the Minimum Bid Price Requirement or other applicable Nasdaq listing rules.
• There is no assurance that the company will be able to successfully implement a reverse stock split if it decides to pursue one.
• There is no assurance that the Nasdaq Hearing Panel will grant the company's request for a suspension of delisting.
• There is no assurance that the company's appeal of the delisting determination will be successful.
• If the company's securities are delisted from Nasdaq, it could become more difficult to buy or sell the common stock or obtain accurate quotations.
• Delisting could lead to a material decline in the price of the company's common stock.
• Delisting could impair the company's ability to raise capital.
• Delisting could trigger defaults and penalties under outstanding agreements or securities of the company.
• The timing of the hearing and the Panel's decision may be quicker than expected.

Future Outlook

The company intends to appeal Nasdaq's delisting determination and expects the appeal process to stay the suspension of trading. It plans to present a strategy to regain compliance, which may include a reverse stock split, subject to board and stockholder approval. However, there is no assurance that the company will successfully regain compliance or that its appeal will be successful.

Management Comments

• "The Company intends to request a hearing before the Panel at which it will request a suspension of delisting pending its return to compliance."
• "The Company expects that its hearing request will stay the suspension of trading and delisting of the common stock pending the conclusion of the hearing process."
• "The Company intends to provide a plan to regain compliance to the Panel, including, subject to approval of the Companys Board of Directors and its stockholders, implementing a reverse stock split, should it be necessary."

Industry Context

This situation is common for smaller biotechnology or development-stage companies listed on Nasdaq, which often struggle to maintain minimum bid prices and sufficient stockholders' equity due to ongoing R&D expenses and lack of significant revenue. Such delisting notices highlight the financial pressures and compliance challenges faced by companies that do not achieve commercial success or secure sufficient funding to meet exchange requirements.

Comparison to Industry Standards

• Nasdaq's minimum bid price of $1.00 and minimum stockholders' equity of $5,000,000 are standard continued listing requirements for The Nasdaq Capital Market. Many small-cap companies, particularly in the biotech sector, face challenges in consistently meeting these thresholds, especially during prolonged periods of R&D without significant commercialization.
• Companies like IMUNON, which are in the clinical development stage, often rely on capital raises to fund operations, making compliance with equity requirements difficult if market capitalization declines or losses accumulate.
• The proposed reverse stock split is a common strategy employed by companies in similar situations (e.g., Sorrento Therapeutics, Athersys, Inc. in the past) to artificially increase their share price to meet bid price requirements, though it does not address underlying business fundamentals.

Stakeholder Impact

• Shareholders: Potential for significant decline in stock price, reduced liquidity, and difficulty in buying/selling shares if delisted. Uncertainty regarding the outcome of the appeal and potential reverse stock split.
• Creditors/Partners: Delisting could trigger defaults and penalties under existing agreements, potentially impacting the company's financial stability and ability to meet obligations.

Next Steps

• IMUNON to request a hearing before a Nasdaq Hearing Panel by June 4, 2025.
• IMUNON to present a plan to regain compliance to the Panel.
• Potential implementation of a reverse stock split, subject to Board and stockholder approval.
• Nasdaq Hearing Panel to render a decision following the hearing.

Key Dates

Recommendation

Keywords

IMUNON, IMNN, Nasdaq, Delisting, Minimum Bid Price, Stockholders Equity, Reverse Stock Split, SEC Filing, 8-K, Biotechnology, Compliance, Capital Market